GLP-1受体激动剂和急性胰腺炎:事实还是夸张的风险?
Juan Enrique Domínguez Muñoz1, José Lariño Noia2, Yessica Domínguez Novoa1
1Gastroenterology and Hepatology, Fundación Instituto de Investigación Sanitaria de Santiago (IDIS), España.
Revista espanola de enfermedades digestivas
|September 29, 2025
概括
类似葡萄糖类-1受体激动剂 (GLP-1RA) 有效地控制2型糖尿病和体重. 然而,这些流行的药物通常会导致胃肠道问题,可能与胰腺炎有关.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RA) 是治疗2型糖尿病 (T2DM) 和肥胖的关键治疗方法.
- 这些药物模仿隐激素GLP-1,影响葡萄糖平衡,食欲和胃运动.
- 扩展的适应症包括心脏代谢性疾病和与代谢相关的脂肪性肝病 (MASLD).
研究的目的:
- 审查GLP-1RA的疗效和安全性概况.
- 突出与GLP-1 RA治疗相关的常见不良事件和新出现的安全问题.
主要方法:
- 对GLP-1RA的临床试验和观察性研究的文献综述.
- 对T2DM,体重管理和其他疾病报告的疗效的分析.
- 评估安全数据,重点关注胃肠道副作用和胰腺炎风险.
主要成果:
- GLP-1 RAs在血糖控制和减肥方面显示出显著的益处.
- 胃肠道不良反应,如恶心,吐和腹,影响高达80%的用户,通常取决于剂量.
- 与急性胰腺炎的潜在关联需要进一步调查.
结论:
- GLP-1RA是一种有价值的治疗剂,具有广泛的应用.
- 管理剂量依赖的胃肠道副作用对于患者的坚持至关重要.
- 需要进行持续的研究,以充分阐明GLP-1 RA使用时的胰腺炎风险.
相关概念视频
Glucagon-like Receptor Agonists
809
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
809
Acute Pancreatitis I: Introduction
1.1K
Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
1.1K
Acute Pancreatitis II: Clinical Manifestations and Management
693
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
693
Dipeptidyl Peptidase 4 Inhibitors
540
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
540
Oral Hypoglycemic Agents: Glinides
554
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
554
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
496
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
496


